No abstract available.
Coronary Disease* ; Secondary Prevention*

No abstract available.
Endothelium* ; Hemostasis* ; Hydroxymethylglutaryl-CoA Reductase Inhibitors* ; Inflammation*

No abstract available.
Atherosclerosis* ; Female ; Hormone Replacement Therapy* ; Humans

No abstract availalbe.

No abstract available.
Coronary Vessels* ; Electrocardiography* ; Spasm*

No abstract available.
Coronary Vasospasm* ; Heart Arrest* ; Verapamil*

No abstract available.
Coronary Vessels* ; Echocardiography, Transesophageal* ; Sinus of Valsalva*

No abstract available.
Estrogens* ; Female ; Humans

Supravalvular aortic stenosis may be defined as an obstructive congenital deformity of the ascending aorta whitch originates just distal to the level of the origins of the coronary arteries, and whitch includes a wide spectrum of pathologic changes. A 27 years-old-female was admitted because of further evaluation of known some heart disease. Clinical diagnosis of supravalvular aortic stenosis was made by echocardiography and angiography. We presented a case of supravalvular aortic stenosis with a review of literature.
Angiography ; Aorta ; Aortic Stenosis, Supravalvular* ; Congenital Abnormalities ; Coronary Vessels ; Diagnosis ; Echocardiography ; Heart Diseases

Lowering low-density lipoprotein-cholesterol (LDL-C) is the primary target to prevent cardiovascular events in patients with dyslipidemia at high risk for cardiovascular disease. Many patients on statin therapy have initial or recurrent coronary heart disease events despite reductions in LDL-C. Indeed, 2/3 of patients on statin therapy suffer from residual risk. Low high-density lipoprotein-cholesterol (HDL-C) and high triglycerides levels are modifiable and important factors to resolve a residual risk. Especially, low serum levels of HDL-C (< 40 mg/dL for men, < 50 mg/dL for women) are highly prevalent and are recognized as an independent risk factor for cardiovascular morbidity (myocardial infarction, stroke, peripheral arterial disease, and restenosis after coronary stenting) and mortality. Thus, therapy focusing on raising HDL-C may be an important paradigm for treating and slowing progression of atherosclerosis, coronary heart disease, and co-morbid metabolic disorders. In this review, we discuss the importance of HDL-C based on experimental and large scaled clinical trials.
Cardiovascular Diseases ; Cholesterol ; Coronary Artery Disease ; Coronary Disease ; Dyslipidemias ; Heart Diseases ; Humans ; Hydroxymethylglutaryl-CoA Reductase Inhibitors ; Infarction ; Lipoproteins ; Male ; Peripheral Arterial Disease ; Risk Factors ; Stroke ; Triglycerides